US Stock MarketDetailed Quotes

VKTX Viking Therapeutics

Watchlist
  • 56.780
  • +1.010+1.81%
Trading Aug 9 10:33 ET
6.29BMarket Cap-61053P/E (TTM)

Viking Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
(Q3)Sep 30, 2022
Total revenue
0
0
0
0
0
0
0
0
0
0
Operating revenue
--0
--0
--0
--0
--0
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
43.45%34.05M
65.91%34.07M
43.31%100.83M
44.38%29.29M
68.34%27.27M
34.65%23.74M
26.42%20.54M
26.35%70.36M
62.13%20.28M
20.84%16.2M
Selling and administrative expenses
4.70%10.29M
4.63%9.97M
129.64%37.02M
113.96%8.78M
109.72%8.89M
140.23%9.82M
158.24%9.53M
50.65%16.12M
54.15%4.11M
62.46%4.24M
-General and administrative expense
4.70%10.29M
4.63%9.97M
129.64%37.02M
113.96%8.78M
109.72%8.89M
140.23%9.82M
158.24%9.53M
50.65%16.12M
54.15%4.11M
62.46%4.24M
Research and development costs
70.79%23.77M
118.96%24.1M
17.65%63.81M
26.73%20.5M
53.68%18.38M
2.77%13.92M
-12.32%11.01M
20.57%54.23M
64.29%16.18M
10.78%11.96M
Operating profit
-43.45%-34.05M
-65.91%-34.07M
-43.31%-100.83M
-44.38%-29.29M
-68.34%-27.27M
-34.65%-23.74M
-26.42%-20.54M
-26.35%-70.36M
-62.13%-20.28M
-20.84%-16.2M
Net non-operating interest income expense
161.40%11.8M
567.69%6.72M
875.95%14.93M
546.41%4.68M
1,018.44%4.73M
1,773.44%4.52M
608.45%1.01M
123.36%1.53M
392.52%724K
164.38%423K
Non-operating interest income
159.95%11.82M
552.32%6.75M
845.25%15.02M
542.90%4.71M
951.78%4.73M
--4.55M
571.43%1.03M
126.03%1.59M
360.38%732K
260.00%450K
Total other finance cost
-43.75%18K
0.00%28K
49.15%88K
225.00%26K
-92.59%2K
113.28%32K
133.33%28K
227.78%59K
-33.33%8K
177.14%27K
Other net income (expense)
2K
-700.00%-42K
0
Gain on sale of security
--2K
----
----
----
----
----
----
-700.00%-42K
--0
----
Income before tax
-15.73%-22.25M
-40.06%-27.36M
-24.73%-85.9M
-25.80%-24.61M
-42.86%-22.53M
-10.29%-19.23M
-21.29%-19.53M
-25.24%-68.87M
-58.30%-19.56M
-19.10%-15.77M
Income tax
Net income
-15.73%-22.25M
-40.06%-27.36M
-24.73%-85.9M
-25.80%-24.61M
-42.86%-22.53M
-10.29%-19.23M
-21.29%-19.53M
-25.24%-68.87M
-58.30%-19.56M
-19.10%-15.77M
Net income continuous Operations
-15.73%-22.25M
-40.06%-27.36M
-24.73%-85.9M
-25.80%-24.61M
-42.86%-22.53M
-10.29%-19.23M
-21.29%-19.53M
-25.24%-68.87M
-58.30%-19.56M
-19.10%-15.77M
Minority interest income
Net income attributable to the parent company
-15.73%-22.25M
-40.06%-27.36M
-24.73%-85.9M
-25.80%-24.61M
-42.86%-22.53M
-10.29%-19.23M
-21.29%-19.53M
-25.24%-68.87M
-58.30%-19.56M
-19.10%-15.77M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-15.73%-22.25M
-40.06%-27.36M
-24.73%-85.9M
-25.80%-24.61M
-42.86%-22.53M
-10.29%-19.23M
-21.29%-19.53M
-25.24%-68.87M
-58.30%-19.56M
-19.10%-15.77M
Basic earnings per share
-5.26%-0.2
-4.00%-0.26
-1.11%-0.91
3.85%-0.25
-9.52%-0.23
17.39%-0.19
-19.05%-0.25
-26.76%-0.9
-62.50%-0.26
-23.53%-0.21
Diluted earnings per share
-5.26%-0.2
-4.00%-0.26
-1.11%-0.91
3.85%-0.25
-9.52%-0.23
17.39%-0.19
-19.05%-0.25
-26.76%-0.9
-62.50%-0.26
-23.53%-0.21
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
--
(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022(Q3)Sep 30, 2022
Total revenue 0000000000
Operating revenue --0--0--0--0--0--0--0--0--0--0
Cost of revenue
Gross profit
Operating expense 43.45%34.05M65.91%34.07M43.31%100.83M44.38%29.29M68.34%27.27M34.65%23.74M26.42%20.54M26.35%70.36M62.13%20.28M20.84%16.2M
Selling and administrative expenses 4.70%10.29M4.63%9.97M129.64%37.02M113.96%8.78M109.72%8.89M140.23%9.82M158.24%9.53M50.65%16.12M54.15%4.11M62.46%4.24M
-General and administrative expense 4.70%10.29M4.63%9.97M129.64%37.02M113.96%8.78M109.72%8.89M140.23%9.82M158.24%9.53M50.65%16.12M54.15%4.11M62.46%4.24M
Research and development costs 70.79%23.77M118.96%24.1M17.65%63.81M26.73%20.5M53.68%18.38M2.77%13.92M-12.32%11.01M20.57%54.23M64.29%16.18M10.78%11.96M
Operating profit -43.45%-34.05M-65.91%-34.07M-43.31%-100.83M-44.38%-29.29M-68.34%-27.27M-34.65%-23.74M-26.42%-20.54M-26.35%-70.36M-62.13%-20.28M-20.84%-16.2M
Net non-operating interest income expense 161.40%11.8M567.69%6.72M875.95%14.93M546.41%4.68M1,018.44%4.73M1,773.44%4.52M608.45%1.01M123.36%1.53M392.52%724K164.38%423K
Non-operating interest income 159.95%11.82M552.32%6.75M845.25%15.02M542.90%4.71M951.78%4.73M--4.55M571.43%1.03M126.03%1.59M360.38%732K260.00%450K
Total other finance cost -43.75%18K0.00%28K49.15%88K225.00%26K-92.59%2K113.28%32K133.33%28K227.78%59K-33.33%8K177.14%27K
Other net income (expense) 2K-700.00%-42K0
Gain on sale of security --2K-------------------------700.00%-42K--0----
Income before tax -15.73%-22.25M-40.06%-27.36M-24.73%-85.9M-25.80%-24.61M-42.86%-22.53M-10.29%-19.23M-21.29%-19.53M-25.24%-68.87M-58.30%-19.56M-19.10%-15.77M
Income tax
Net income -15.73%-22.25M-40.06%-27.36M-24.73%-85.9M-25.80%-24.61M-42.86%-22.53M-10.29%-19.23M-21.29%-19.53M-25.24%-68.87M-58.30%-19.56M-19.10%-15.77M
Net income continuous Operations -15.73%-22.25M-40.06%-27.36M-24.73%-85.9M-25.80%-24.61M-42.86%-22.53M-10.29%-19.23M-21.29%-19.53M-25.24%-68.87M-58.30%-19.56M-19.10%-15.77M
Minority interest income
Net income attributable to the parent company -15.73%-22.25M-40.06%-27.36M-24.73%-85.9M-25.80%-24.61M-42.86%-22.53M-10.29%-19.23M-21.29%-19.53M-25.24%-68.87M-58.30%-19.56M-19.10%-15.77M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -15.73%-22.25M-40.06%-27.36M-24.73%-85.9M-25.80%-24.61M-42.86%-22.53M-10.29%-19.23M-21.29%-19.53M-25.24%-68.87M-58.30%-19.56M-19.10%-15.77M
Basic earnings per share -5.26%-0.2-4.00%-0.26-1.11%-0.913.85%-0.25-9.52%-0.2317.39%-0.19-19.05%-0.25-26.76%-0.9-62.50%-0.26-23.53%-0.21
Diluted earnings per share -5.26%-0.2-4.00%-0.26-1.11%-0.913.85%-0.25-9.52%-0.2317.39%-0.19-19.05%-0.25-26.76%-0.9-62.50%-0.26-23.53%-0.21
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ----Unqualified Opinion--------Unqualified Opinion----

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg
Concept Weight Loss Drugs
Weight Loss Drugs
Intraday+4.14%